Why compare them?
These records are compared to clarify how their mechanisms, research areas, and evidence maturity differ.
Simple first. Deeper when you want it.
Understand the differences that matter.
See the biggest similarities, differences, strengths, limitations, and unanswered questions first—then open the evidence behind them.
Compound comparison
Semax vs. Tirzepatide
Understand the meaningful overlap, differences, evidence, and unknowns—then go deeper only when you want to.
60-Second Summary
The answer first
Current evidenceComparable evidence base
No direct head-to-head study is represented. This comparison uses separate evidence records that may differ in population, duration, route, dose, and endpoint.
✓ Shared
Shared Similarities
- Both are included in the Relay research library, but their current records answer substantially different questions.
⇄ Different
Biggest Difference
Semax is distinguished by semax is an ACTH-fragment-derived heptapeptide with limited human brain-imaging and stroke-rehabilitation literature, not an FDA-approved nootropic or neuroprotective medicine; Tirzepatide is distinguished by dual agonist at GIP and GLP-1 receptors, with approved U.S. products and a much larger completed evidence base.
? Unknown
Biggest Unknown
No direct head-to-head study establishes how these compounds compare under the same population, dose, duration, and endpoints.
Key Takeaways
Semax is distinguished in the current record by semax is an ACTH-fragment-derived heptapeptide with limited human brain-imaging and stroke-rehabilitation literature, not an FDA-approved nootropic or neuroprotective medicine. Tirzepatide is distinguished by dual agonist at GIP and GLP-1 receptors, with approved U.S. products and a much larger completed evidence base. Neither is objectively “better”; the useful question is which evidence record addresses the research question being asked.
Research matrix
Which question has stronger current support?
Research questionStronger current supportExplanation
Human evidenceTirzepatide
Semax: Early and limited human evidence. Tirzepatide: Mature human evidence.
Regulatory historyTirzepatide
Semax: Registered in Russia; not FDA approved; final U.S. 503A action pending. Tirzepatide: FDA approved for defined indications.
Mechanistic breadthSemax
More named targets describes mechanistic breadth; it does not establish greater effectiveness.
Direct comparisonUnknown
Separate studies cannot establish comparative superiority.
Deeper when you want it
Explore the evidence and nuance
Best-studied areas and pathway mapSee shared targets, unique pathways, and the research questions attached to each record.
Semax
- Resting-state brain-network imaging
- Ischemic-stroke rehabilitation and acute recovery
- Cerebral-ischemia models
- Learning and neurotrophin biology in animals
Tirzepatide
- Obesity
- Type 2 diabetes
- Cardiometabolic outcomes
Pathway and research map
Shared foundation and unique questions
Research confidence by questionCompare regulatory, human-evidence, outcome, and administration records side by side.
Question by question
What each evidence base can actually answer
Regulatory statusEvidence, not a winner
SemaxNot FDA approved; PCAC recommendation
Registered as a medicine in Russia but not FDA approved. PCAC recommended possible 503A inclusion for Semax free base and acetate on July 24, 2026; the recommendation is nonbinding and no final FDA action was located by July 25.
TirzepatideFDA-labeled indications
FDA approved as Mounjaro for type 2 diabetes and Zepbound for defined adult weight-management and OSA indications.
Evidence depthEvidence, not a winner
SemaxSmall/older human reports
One small acute fMRI comparison, older and methodologically limited stroke reports, an uncontrolled facial-pain report summarized by FDA, and substantially broader animal and laboratory research.
TirzepatideMature Phase 3
Multiple large Phase 3 trials, active-comparator studies, 176-week follow-up, a 13,299-participant cardiovascular outcomes trial, and newer 2026 maintenance data.
Weight outcomesEvidence, not a winner
SemaxNo controlled evidence
No controlled human evidence for weight loss, appetite control, or body recomposition was located.
TirzepatidePeer-reviewed Phase 3
SURMOUNT-1 peer-reviewed trial: mean change −15.0%, −19.5%, and −20.9% across studied doses versus −3.1% placebo at 72 weeks.
Type 2 diabetesEvidence, not a winner
SemaxNo controlled evidence
No controlled human evidence for glycaemic control or diabetes outcomes was located.
TirzepatideApproved + Phase 3
Extensive SURPASS program and FDA approval. SURPASS-2 directly compared tirzepatide with semaglutide 1 mg in type 2 diabetes.
Obstructive sleep apnoeaEvidence, not a winner
SemaxNo controlled evidence
No controlled human obstructive-sleep-apnoea evidence was located.
TirzepatideApproved + Phase 3
Two peer-reviewed Phase 3 trials support the FDA-approved Zepbound indication for moderate-to-severe OSA in adults with obesity.
Cardiovascular outcomesEvidence, not a winner
SemaxNo outcomes program
No cardiovascular-outcomes program was located. Stroke-recovery reports do not establish prevention of cardiovascular or cerebrovascular events.
TirzepatideCVOT + HFpEF trial
SURPASS-CVOT found tirzepatide noninferior—but not superior—to dulaglutide for major cardiovascular events. In SUMMIT, a separate placebo-controlled HFpEF-and-obesity population had fewer composite cardiovascular-death or worsening-heart-failure events; that finding is population-specific.
Administration and handlingEvidence, not a winner
SemaxIntranasal studies only
Located human reports used intranasal administration. Study exposures are not dosing guidance, no FDA-approved regimen exists, and no regulator-approved consumer reconstitution or storage process was located.
TirzepatideOfficial FDA label
FDA labels provide product-specific once-weekly subcutaneous dosing and handling. Approved presentations are solutions; no reconstitution is required.
Comparison limitationsUnderstand what this comparison cannot establish before interpreting separate studies.
Comparable evidence base
- No direct head-to-head trial is represented for this pair.
- Separate studies may use different populations, endpoints, durations, doses, routes, and estimands.
- Results should not be interpreted as comparative superiority or individual guidance.
Current unknowns
Questions the evidence cannot answer yet
- Whether any promoted cognitive or neuroprotective effect is clinically meaningful and durable in humans, and what formulation-specific safety, pharmacokinetics, and product quality look like.
- Long-term individual durability and rare events, plus evidence for uses outside studied and approved populations.
Community Intelligence
Emerging patterns, clearly separated from evidence
Semax
No community experiences yetBe the first account holder to contribute.
Tirzepatide
No community experiences yetBe the first account holder to contribute.
Community Intelligence summarizes structured, self-reported experiences. It can reveal patterns and useful research questions, but it cannot prove safety, effectiveness, or cause and effect. Published evidence is always shown separately.